Key facts
- This page summarizes Robert J. Lefkowitz MD's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 May 2024, 16:03.
Robert J. Lefkowitz MD - 13 May 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- Director
- Issuer ticker
- LXRX
- Reported as of
- 13 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 May 2024, 16:03:08 UTC
- Prior SEC filing
- 29 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert J. Lefkowitz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert J. Lefkowitz MD filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 13 May 2024.
Change
- Previous filing in this sequence was filed on 29 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +44,906
- Change %
- Price
- $0.000000
- Shares after
- 44,906
- Date
- 13 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 44,906
- Exercise price
- $1.79
- Footnotes
- F1
LXRX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +36,810
- Change %
- Price
- $0.000000
- Shares after
- 36,810
- Date
- 13 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 36,810
- Exercise price
- $0.000000
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.
Footnote F2
Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of common stock.